RAPT Therapeutics (NASDAQ:RAPT) Stock, Quote.Headers.trade-ideas

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

oil-prices-5079975

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ARMK

CERO

EFSH

MARA

RAPT

SPNS

Crude Oil Down 3%; Aramark Posts Upbeat Earnings

Wall-Street-dall

MNDY

Nasdaq Moves Lower; Canaan Shares Surge

bz_pharma_briefs

Biotech

Health Care

Movers

General

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient&#39;s Liver Injury

RAPT Therapeutics Inc

As previously reported, JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral after the company announced th...

JPMorgan cuts Rapt Therapeutics to Underweight after zelnecirnon discontinued

Piper Sandler analyst Edward Tenthoff downgraded Rapt Therapeutics (RAPT) to Neutral from Overweight with a price target of $2, down from $8, after...

Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on RAPT Therapeutics (RAPT – Research Report), with a price targ...

RAPT Therapeutics: Strategic Shift to Next-Gen Compounds Boosts Buy Rating Despite Program Termination

On July 16, 2024, the Company's board of directors approved a reduction of the Company's workforce to conserve cash resources. The workforce reduct...

Rapt Therapeutics reports Q3 EPS (47c), consensus (56c)

RAPT Therapeutics GAAP EPS of -$0.47 beats by $0.11

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Rapt Therapeutics Inc ( ($RAPT) ) has released its Q3 earnings. Here is a breakdown of the information Rapt Therapeutics Inc presented to its inves...

RAPT Therapeutics Reports Improved Q3 2024 Results

RAPT Therapeutics ( ($RAPT) ) has issued an announcement. RAPT Therapeutics has approved a repricing of underwater options for its employees, signi...

RAPT Therapeutics Reprices Underwater Employee Stock Options

TimesSquare U.S. Small/Mid Cap Growth Q3 2024 Commentary

ASND

ATRC

AXSM

BMBL

CTOR

CTXR

CYBR

EXPO

FIVE

FROG

FRPT

FULC

GLBE

HRTX

KRYS

MNOV

MSTR

MTDR

NICE

ONCY

ONTO

PHAT

RGEN

SMAR

SMCI

SNYNF

SYNA

SYRS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

HOOKIPA Pharma

iBio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kala Bio

Longeveron

Lantern Pharma

Marker Therapeutics

NextCure

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Pluri

RenovoRx

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Exicure

Wells Fargo

Barclays

Leerink Partners

Berenberg

Comments

RAPT Therapeutics

RAPT Therapeutics (RAPT) Forecast

RAPT Therapeutics (NASDAQ:RAPT) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga